Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01 [Yahoo! Finance]
Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation [Yahoo! Finance]
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01